RMC-9805 is a tricomplex KRAS G12D-ON inhibitor that demonstrated significant tumor regression in KRAS G12D-mutant solid tumors, including NSCLC xenograft models, and is now undergoing a phase I trial to better evaluate its safety and efficacy [41]. Here, KRAS is linked to neoplasm.